GPIHBP1 CRISPR/Cas9 KO Plasmid (h): sc-403473
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GPIHBP1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the GPIHBP1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: GPIHBP1 Antibody (F-4): sc-376598
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GPIHBP1 CRISPR/Cas9 KO Plasmid (h) | sc-403473 | 20 µg | $397.00 |
Overview
GPIHBP1 (glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1) is an endothelial cell-surface protein that captures lipoprotein lipase (LPL) and facilitates its transport to the capillary lumen, enabling intravascular hydrolysis of triglyceride-rich lipoproteins. By organizing the LPL processing axis at the endothelium, GPIHBP1 is central to lipid uptake and clearance pathways that regulate plasma triglyceride homeostasis. Disruption of GPIHBP1 function is associated with severe hypertriglyceridemia and impaired chylomicron/VLDL processing, linking this gene to dyslipidemia-related metabolic phenotypes. As such, GPIHBP1 is widely studied in vascular biology, lipoprotein metabolism, and mechanisms governing endothelial handling of lipid cargo.
GPIHBP1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the GPIHBP1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the GPIHBP1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the GPIHBP1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GPIHBP1 protein expression.
This CRISPR knockout system enables efficient generation of GPIHBP1-deficient cell models for investigation of GPIHBP1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting GPIHBP1 exon(s) critical for GPIHBP1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple GPIHBP1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by GPIHBP1 CRISPR/Cas9 KO Plasmid (h) and GPIHBP1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the GPIHBP1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by GPIHBP1 HDR Plasmid (h) and GPIHBP1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by GPIHBP1 homology arms to support homology-directed repair at defined GPIHBP1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.